Using Continuous Glucose Monitoring to Predict Prediabetes in People with Cystic Fibrosis Aged 12 to 55

What this Trial Is About

Researchers are studying people with cystic fibrosis to develop a model using continuous glucose monitoring CGM that can predict the progression from prediabetes to diabetes. This pilot study focuses on individuals aged 12 to 55 years who have cystic fibrosis and either no diabetes or prediabetes. The goal is to better understand how glucose levels change in these groups to improve early detection of diabetes related to cystic fibrosis. Participants will take part in a one-time oral glucose tolerance test OGTT and wear a CGM device for up to 10 days to collect glucose data. The study includes two groups people with cystic fibrosis without diabetes and those with cystic fibrosis-related prediabetes. People with cystic fibrosis-related diabetes already using CGM will have their personal CGM data collected without additional tests. During the study, participants will use a CGM device linked to a compatible smartphone to monitor glucose levels continuously. Researchers will analyze the data to create a CGM Dynamic Index CDI that predicts prediabetes progression. The main outcome is the CDI measured over 10 days. The study does not involve randomization or masking, and participant safety and glucose data accuracy will be monitored throughout the process.

CGM Dynamic Index for Predicting Prediabetes in Cystic Fibrosis